Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have received a consensus recommendation of “Moderate Buy” from the five research firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $4.80.

KPTI has been the topic of a number of research analyst reports. StockNews.com raised Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Robert W. Baird lowered their target price on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. Royal Bank of Canada reiterated an “outperform” rating and issued a $3.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. Finally, HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th.

Karyopharm Therapeutics Stock Performance

Shares of Karyopharm Therapeutics stock opened at $0.77 on Friday. The company has a 50-day simple moving average of $0.89 and a two-hundred day simple moving average of $1.09. The stock has a market capitalization of $96.05 million, a PE ratio of -0.61 and a beta of 0.21. Karyopharm Therapeutics has a 52-week low of $0.62 and a 52-week high of $1.95.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.09. The firm had revenue of $42.79 million during the quarter, compared to analysts’ expectations of $36.07 million. As a group, equities research analysts forecast that Karyopharm Therapeutics will post -1.16 EPS for the current fiscal year.

Insider Buying and Selling at Karyopharm Therapeutics

In related news, Director Deepika Pakianathan sold 468,044 shares of the firm’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $0.96, for a total value of $449,322.24. Following the transaction, the director now owns 3,385 shares of the company’s stock, valued at $3,249.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold a total of 1,074,687 shares of company stock worth $1,043,723 in the last three months. 4.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in KPTI. Point72 DIFC Ltd bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter valued at $31,000. Simplicity Wealth LLC bought a new stake in Karyopharm Therapeutics during the first quarter valued at about $66,000. Monashee Investment Management LLC purchased a new stake in Karyopharm Therapeutics in the fourth quarter worth about $115,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Karyopharm Therapeutics in the second quarter worth about $143,000. Finally, Acadian Asset Management LLC purchased a new position in shares of Karyopharm Therapeutics during the 2nd quarter valued at about $167,000. 66.44% of the stock is currently owned by institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).